

Solaris

Vermont New Product Launch Report

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
73473-0309-10	Tazarotene External Gel 0.05 % Package Size 100 Package Quantity 1	2/15/2023
73473-0310-10	Tazarotene External Gel 0.1 % Package Size 100 Package Quantity 1	2/15/2023

WAC AT INTRODUCTION	MARKETING PRICING PLAN
1316.71	Confidential Trade Secret Information of Solaris Pharma, not for public disclosure: The marketing plans for the launch of Tazarotene External Gel 0.5%™ includes: This is an ANDA/generic drug which is a direct AB substitution for the branded product. All customer acquisition will be through substitution at the retail pharmacy formularies. Pricing is a discount off of current branded pricing.
1399.07	Confidential Trade Secret Information of Solaris Pharma, not for public disclosure: The marketing plans for the launch of Tazarotene External Gel 0.1%™ includes: This is an ANDA/generic drug which is a direct AB substitution for the branded product. All customer acquisition will be through substitution at the retail pharmacy formularies. Pricing is a discount off of current branded pricing.

MARKETING PRICING NONPUBLIC	ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR
Y	Drug is prescribed for psoriasis which affects 7.5 Million people in the US annually. The current market data in the US shows approx. 30,000 units sold so actual users may be limited.	N
Y	Drug is prescribed for psoriasis which affects 7.5 Million people in the US annually. The current market data in the US shows approx. 30,000 units sold so actual users may be limited.	N

PRIORITY REVIEW INDICATOR	ACQUISITION DATE	ACQUISITION PRICE
N	N/A	N/A
N	N/A	N/A

ACQUISITION PRICE NONPUBLIC	ACQUISITION PRICE COMMENT
N/A	N/A
N/A	N/A

GENERAL COMMENTS
N/A
N/A